Because cisplatin and carboplatin were prioritized for patients with curable cancers during the shortage, the researchers ...

During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, there was no difference in mortality rates among patients with advanced cancer compared ...

During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, there was no ...

An analysis of national data found that short-term mortality was not impacted for patients with advanced cancers during the shortage of the generic platinum chemotherapy drugs cisplatin and ...

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of ...

Teos' Phase II trial for inupadenant met its primary and secondary endpoints but offered little more than existing treatments ...

Teos Therapeutics (ITOS) announced the presentation of clinical, translational, and preclinical data from its adenosine A2A receptor ...

Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts- Recommended ...

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of ...